6-Minute Walk Test (6MWT)


Indications

Evaluation for Altitude-Associated Hypoxemia During Air Travel in Patients with Cardiopulmonary Disease (see High Altitude)

Clinical Data

  • Comparative Study of 6MWT and Hypoxia Altitude Simulation Test (HAST) in Patients with Either Interstitial Lung Disease or COPD (Aviat Space Environ Med, 2007) [MEDLINE]
    • Oxygen Desaturation Induced by the 6MWT Correlated with that After HAST (r = 0.52)
  • Study of Algorithm Using Resting/6WMT SpO2 and HAST in COPD Patients (Thorax, 2012) [MEDLINE]
    • Baseline SpO2 <92%: supplemental oxygen is required for air travel
    • Baseline SpO2 92-95%
      • 6MWT SpO2 <84%: supplemental oxygen is required for air travel
      • 6MWT SpO2 ≥84%:
        • HAST SpO2 ≤85%: supplemental oxygen is required for air travel
        • HAST SpO2 >85%: no supplemental oxygen is required for air travel
    • Baseline SpO2 >95%
      • 6MWT SpO2 <84%
        • HAST SpO2 ≤85%: supplemental oxygen is required for air travel
        • HAST SpO2 >85%: no supplemental oxygen is required for air travel
      • 6MWT SpO2 ≥84%: no supplemental oxygen is required for air travel

Evaluation of Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease)

  • Clinical Efficacy
    • ECLIPSE Trial (2013) [MEDLINE]
      • 6MWT with a 30 m (98.4 ft) Decline in 6MWT Distance in the First Year was Associated with an Increased Risk for Mortality in the Subsequent 2 yrs
      • 6MWT Had No Significant Association with Frequency of Hospitalization Due to COPD Exacerbation
      • 6MWT Had a Weak Associations with Decline in FEV1
      • 6MWT Had a Weak Association with Decline in St George’s Respiratory Questionnaire (SGRQ) Criteria

Evaluation of Idiopathic Pulmonary Fibrosis (IPF) (see Idiopathic Pulmonary Fibrosis, [[Idiopathic Pulmonary Fibrosis]])

Evaluation of Pulmonary Hypertension (see Pulmonary Hypertension)

  • xxxx

Technique


Adverse Effects/Complications

Pulmonary Adverse Effects/Complications


References